Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients

The administration announced deals with nine major drugmakers (Amgen, BMS, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novartis, Sanofi) to align U.S. prices with most-favored-nation (MFN) levels, give every state Medicaid access to MFN pricing, and require repatriation of increased foreign revenue and deep discounts for direct-to-consumer purchases via “TrumpRx.” The agreements include steep list-price cuts (examples: Gilead Epclusa $24,920→$2,425; Novartis Mayzent $9,987→$1,137; Sanofi Plavix $756→$16; Amgen Repatha $573→$239) and a collective commitment of at least $150 billion in U.S. manufacturing investment plus API donations (GSK 98.8 kg albuterol; BMS 6.5 tons apixaban; Merck 3.5 tons ertapenem). The measures are likely to pressure U.S. pharma margins while producing sizable Medicaid and patient cost savings and could materially re-rate sector stocks focused on U.S. pricing exposure.

Analysis

Market structure: Direct winners are U.S. payers and Medicaid programs (immediate cash savings) and low‑margin direct‑to‑consumer channels (TrumpRx); direct losers are high‑priced branded drug franchises—examples show list cuts up to ~90% (Gilead Epclusa) which implies product‑level revenue collapses. Company‑level impact will vary: single‑drug franchises can see 30–80% product revenue decline; diversified giants may face 3–12% EBITDA compression over 12–24 months depending on product concentration and pass‑through to payers.

Competitive dynamics & supply/demand: MFN and direct‑sale discounts remove price insulation, shifting bargaining power to government and consumers; expect volume increases for low‑price channels but substantial margin erosion. Increased U.S. capex ($150bn pledged) will tighten API/CMO capacity in the medium term, benefiting contract manufacturers while raising pharma operating costs near term.

Risk assessment & catalysts: Tail risks include aggressive legislative expansion (full Medicare price setting), successful industry litigation, or partial policy rollback; these could swing valuations ±20–40% on headlines. Near term (days–weeks) expect elevated volatility around HHS/USTR guidance and upcoming quarterly reports; medium term (3–12 months) watch realized Medicaid uptake and 10‑Q revisions for recurring revenue impacts.

Contrarian/second‑order: Consensus may overstate permanent top‑line loss—companies can delist products from TrumpRx, prioritize launches, raise list prices elsewhere, or absorb shock via rebates; historical OECD reference pricing shocks produced initial selloffs then negotiated recoveries. That implies tactical dislocations (20–30% moves) which create pair‑trade and options opportunities but also a structural downside for firms concentrated in legacy high‑price drugs.

Key Decisions for Investors

• Establish a 2–3% short position in GILD (3–6 month horizon) funded size; rationale: high exposure to marquee HCV franchise (Epclusa example) implies near‑term revenue vulnerability. Trim/exit if stock falls 25% from entry or if formal policy rollback is announced within 60 days.
• Implement a relative value pair: long AMGN (2%) vs short SNY (2%) for 3–9 months — AMGN has lower negative exposure and biologics/PCSK9 franchise is more diversified; close pair if AMGN underperforms SNY by >10% absolute.
• Buy a 3–6 month put‑spread on NVS sized to 1–1.5% notional (10–15% OTM protection, width = max loss) to cap cost while preserving downside if guidance downgrades materialize (monitor 10‑Q/earnings next 30–60 days).
• Reduce overall pharma/biotech beta by 150–300 bps and redeploy 1–2% into U.S. API/CMO exposure (examples: Thermo Fisher (TMO), West Pharmaceutical (WST)) to capture expected medium‑term capex/capacity tailwinds; increase if companies report >5% guidance hits in next quarterly cycle.